Wolfram Brugger
Overview
Explore the profile of Wolfram Brugger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Macdonald A, Scarfe G, Magirr D, Sarvotham T, Charlton J, Brugger W, et al.
Cancer Chemother Pharmacol
. 2019 Feb;
83(4):787-795.
PMID: 30758651
Purpose: Vistusertib is an orally bioavailable dual target of rapamycin complex (TORC) 1/2 kinase inhibitor currently under clinical investigation in various solid tumour and haematological malignancy settings. The pharmacokinetic, metabolic...
12.
Both A, Krauter J, Damm F, Thol F, Gohring G, Heuser M, et al.
Ann Hematol
. 2017 Mar;
96(6):895-904.
PMID: 28331964
Hypomorphic germline variants in TERT, the gene encoding the reverse transcriptase component of the human telomerase complex, occur with a frequency of 3-5% in acute myeloid leukemia. We analyzed the...
13.
Brugger W
Semin Oncol
. 2017 Feb;
31 Suppl 2:33-37.
PMID: 28140108
Advanced follicular and mantle cell lymphoma are currently incurable using conventional chemotherapy. As such, new and potentially more effective therapeutic approaches such as high-dose chemotherapy with autologous stem cell transplantation...
14.
Mey U, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, et al.
Br J Haematol
. 2016 Dec;
176(5):770-782.
PMID: 27983764
The combination of lenalidomide (Revlimid , R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma (rrMM). With this regimen, only a small fraction of patients...
15.
Rittig S, Haentschel M, Weimer K, Heine A, Muller M, Brugger W, et al.
Oncoimmunology
. 2016 Jul;
5(5):e1108511.
PMID: 27467913
Renal cell carcinoma (RCC) is an immunogenic tumor for which immunotherapeutic approaches could be associated with clinically relevant responses. It was recently shown, that induction of T-cell responses against multiple...
16.
Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, et al.
J Thorac Oncol
. 2016 Jan;
11(4):545-55.
PMID: 26773740
Introduction: Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including erlotinib; however, the ability...
17.
Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, et al.
Lancet Oncol
. 2015 Dec;
17(1):57-66.
PMID: 26655425
Background: Fludarabine-based chemoimmunotherapy with rituximab is frequently used in patients with indolent and mantle-cell lymphomas who relapse after alkylating chemotherapy. We aimed to compare the efficacy and safety of rituximab...
18.
Cheson B, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, et al.
Leuk Lymphoma
. 2015 Nov;
57(4):766-82.
PMID: 26592922
Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number...
19.
Stein A, Atanackovic D, Hildebrandt B, Stubs P, Brugger W, Hapke G, et al.
Br J Cancer
. 2015 Sep;
113(6):872-7.
PMID: 26335608
Background: The addition of bevacizumab (BEV) to standard doublet chemotherapy improves outcomes compared with chemotherapy alone in patients with metastatic colorectal cancer (mCRC). The OPAL study examined the effect of...
20.
Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, et al.
Blood
. 2015 Aug;
126(12):1407-14.
PMID: 26239087
Bcl-2/IgH rearrangements can be quantified in follicular lymphoma (FL) from peripheral blood (PB) by polymerase chain reaction (PCR). The prognostic value of Bcl-2/IgH levels in FL remains controversial. We therefore...